The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

• DOI: 10.1038/clpt.2012.57
• Publication Date: 2012-05-23T10:02:41Z
• Authors: R A Wilke; L B Ramsey; S G Johnson; W D Maxwell; H L McLeod; D Voora; R M Krauss; D M Roden; Q Feng; R M Cooper-DeHoff; L Gong; T E Klein; M Wadelius; M Niemi
• Keywords: Pharmacogenomics; SLCO1B1; Guideline; SNP

Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, SLCO1B1 markedly increases systemic exposure to simvastatin and risk muscle toxicity. This guideline explores relationship between rs4149056 (c.521T>C, p.V174A) clinical outcome for all statins. The strength evidence high myopathy with simvastatin. We limit our recommendations accordingly. Clinical Pharmacology & Therapeutics (2012); 92 1, 112–117. doi:10.1038/clpt.2012.57